 The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRTT fully liquid combined hexavalent vaccine HexaximTM administered at 6, 10 and 14 weeks of age in infants born to mothers documented to be serum anti-hepatitis B surface antigen HBsAg serology negative in India. 